Phase 3 Trial of Long-Acting Glatiramer Acetate in Relapsing Multiple Sclerosis
A new Phase 3 randomized clinical trial evaluating a long-acting formulation of glatiramer acetate, for which BNAC served as an Imaging Core Lab center, has been published in Multiple Sclerosis Journal.
The study, “GA Depot, a long-acting glatiramer acetate vs. placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial,” led by Dr. Miller with co-authors including Robert Zivadinov, MD, PhD, BNAC Director,reports results from a multicenter Phase 3 clinical trial investigating GA Depot, a long-acting formulation of glatiramer acetate.
The trial evaluated the safety and efficacy of GA Depot compared with placebo in patients with relapsing multiple sclerosis. Long-acting treatment formulations may offer potential advantages by reducing dosing frequency and improving treatment convenience and adherence for patients living with MS.
This work contributes to ongoing efforts to advance therapeutic options and optimize long-term disease management for individuals affected by multiple sclerosis.
